Posted 4 weeks ago

Sacituzumab Tirumotecan (MK-2870) Plus Pembrolizumab Versus TPC in TNBC Who Did Not Achieve pCR (MK-2870-012)

ClinicalTrials.gov ID NCT06393374

Protocol number MK-2870-012

Sponsor Merck Sharp & Dohme LLC